REGN vs VRTX
REGN and VRTX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | REGNREGENERON PHARMACEUTICALS, INC. | VRTXVERTEX PHARMACEUTICALS INC / MA |
|---|---|---|
| Market cap | — | $130.04B |
| P/E (TTM) | 19.2 | 29.9 |
| P/B | — | 6.42 |
| P/S | — | 10.8x |
| Revenue | $15.53B(TTM) | $12.59B(TTM) |
| Revenue growth (YoY) | 1.0% | 8.9% |
| Net income | $4.33B(TTM) | $4.41B(TTM) |
| Earnings growth (YoY) | 2.1% | 838.1% |
| EPS, diluted | $40.41(TTM) | $17.17(TTM) |
| EBIT margin | 24.9% | 34.8% |
| ROE | 14.2% | 19.5% |
| ROIC | 9.4% | 25.0% |
| 1y total return | +34.7% | +31.1% |
Figures from SEC filings · for reference only · not investment advice
$10,000 투자 성장: REGN vs VRTX
| 지표 | REGN | VRTX |
|---|---|---|
| 최종 가치 | $21.2K | $63.1K |
| 총수익률 | +111.6% | +530.7% |
| CAGR | +7.5% | +19.5% |
| 변동성 | 32.1% | 32.7% |
| 샤프 | 0.26 | 0.58 |
| 소르티노 | 0.38 | 0.86 |
| 최대 낙폭 | -59.7% | -41.6% |
공통 거래일 2600일 기준, 2016-05-13 → 2026-09-16 · 무위험수익률 4.14% (현재 단기 국채 금리, 고정 적용)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)